Analysts at Leerink Partnrs raised their FY2026 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz ...

Research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Waters in a note issued to investors on ...

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...

JPMorgan, Wells Fargo and Leerink acted as joint book running managers for the offering.Maximize Your Portfolio with Data Driven ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...

NeuroPace (Nasdaq:NPCE) today announced that it intends to sell common stock in an underwritten public offering worth $65 ...

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Encompass Health (EHC – Research Report), with a ...

Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

Incorporated (NYSE: ELAN) shares have reached a 52-week low, dipping to $11.11, as the company faces a tumultuous market environment. With a market capitalization of $5.55 billion and a beta of 1.42, ...